Expression of cyclin D1 correlates with malignancy in human ovarian tumours.
Expression of cyclin D1 correlates with malignancy in human ovarian tumours.
复制标题
DOI：
10.1038/bjc.1997.215
复制
发表时间：
1997
影响因子：
8.8
通讯作者：
Alama A
中科院分区：
文献类型：
--
作者：
Barbieri F;Cagnoli M;Ragni N;Pedullà F;Foglia G;Alama A
细胞周期蛋白D1是G1期进展的细胞周期调节因子，已被认为在几种人类癌症类型的发病机制中发挥相关作用。在目前的研究中，细胞周期蛋白D1的表达已被调查的一系列33例，良性（10例），交界性（5例）和恶性（18例）卵巢疾病。Western blotting和RT-PCR分别检测细胞周期蛋白D1蛋白和mRNA的表达。Cyclin D1蛋白在良性疾病患者中检测不到，在大多数交界性疾病患者中检测到，在卵巢癌患者中升高，与恶性程度显著相关（癌与良性，P = 0.0001;良性与交界性，P = 0.0238）。还发现细胞周期蛋白D1表达与肿瘤增殖活性之间存在显著相关性（P = 0.000001）。此外，8个良性病变，两个交界性肿瘤和11个癌被证明是合适的细胞周期蛋白D1转录的分析，和新兴的数据表明蛋白丰度和mRNA表达之间的显着协议。目前的研究结果表明，细胞周期蛋白D1的表达与转化的程度，最有可能发挥作用，在卵巢恶性肿瘤的早期发展。
Cyclin D1 is a cell cycle regulator of G1 progression that has been suggested to play a relevant role in the pathogenesis of several human cancer types. In the current study, the expression of cyclin D1 has been investigated in a series of 33 patients, with benign (10 patients), borderline (five patients) and malignant (18 patients) ovarian disease. Cyclin D1 protein and mRNA content were analysed by Western blotting and reverse transcriptase polymerase chain reaction respectively. The levels of cyclin D1 protein were undetectable in patients with benign disease, detectable in the majority of patients with borderline disease and elevated in those with ovarian carcinomas, being significantly related to the degree of malignancy (carcinoma vs benign, P = 0.0001; benign vs borderline, P = 0.0238). A significant relationship between cyclin D1 expression and tumour proliferative activity was also found (P = 0.000001). Moreover, eight benign lesions, two borderline tumours and 11 carcinomas proved to be suitable for the analysis of cyclin D1 transcript, and emerging data demonstrated significant agreement between protein abundance and mRNA expression. Results from the current study suggest that cyclin D1 expression is associated with the degree of transformation and most probably plays a role in the early development of ovarian malignancy.